Deletion of STAT5a/b in vascular smooth muscle abrogates the male bias in hypoxic pulmonary hypertension in mice: implications in the human disease by Yang, Y. M. et al.
Journal Articles Donald and Barbara Zucker School of MedicineAcademic Works
2015
Deletion of STAT5a/b in vascular smooth muscle
abrogates the male bias in hypoxic pulmonary








See next page for additional authors
Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles
Part of the Medical Molecular Biology Commons
This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for
inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works. For more
information, please contact academicworks@hofstra.edu.
Recommended Citation
Yang Y, Yuan H, Edwards J, Skayian Y, Ochani K, Miller E, Sehgal P. Deletion of STAT5a/b in vascular smooth muscle abrogates the
male bias in hypoxic pulmonary hypertension in mice: implications in the human disease. . 2015 Jan 01; 20():Article 2876 [ p.].
Available from: https://academicworks.medicine.hofstra.edu/articles/2876. Free full text article.
Authors
Y. M. Yang, H. Yuan, J. G. Edwards, Y. Skayian, K. Ochani, E. J. Miller, and P. B. Sehgal
This article is available at Donald and Barbara Zucker School of Medicine Academic Works:
https://academicworks.medicine.hofstra.edu/articles/2876
INTRODUCTION
There is an unusual “estrogen para-
dox” in the pathogenesis of pulmonary
arterial hypertension (PAH) (1–5). The
human disease idiopathic PAH (IPAH)
has a two- to four-fold higher prevalence
in postpubertal women than in men, al-
though women with PAH survive longer
than their male counterparts (1–5). This
female bias in prevalence is observed
even in kindreds of hereditary PAH
(HPAH) in which both the male and fe-
male family members were identified to
have the same mutation in bone morpho-
genetic protein receptor type 2 (BMPR2)
(1–3,6–8). It has been suggested that mu-
tations in cytochrome P450 CYP1B1, an
enzyme involved in estrogen metabolism,
may be a candidate cofactor cocontribut-
ing to the development of the overt dis-
ease (8). However, there is an opposite
male-dominant sex bias in the customar-
ily used rodent models of pulmonary hy-
pertension (PH) (chronic hypoxia,
monocrotaline) such that the male typi-
cally shows higher prevalence and higher
severity than the female (2–5,9–12). Estro-
genic compounds [estradiol-17β (E2), 2-
methoxyestradiol (2-ME)] attenuated de-
velopment of PH in these rodent models
in the male, and ovariectomy of the fe-
male enhanced PH (4). However, in a
converse example, female mice overex-
pressing the serotonin transporter (SERT)
or the S100 calcium-binding protein
S100A4/mts1, but not male mice, sponta-
neously developed PH, with modest in-
creases in right ventricular pressure at 5
months of age (3,7). The mechanisms for
these variations in sex dependence of this
disease in humans and rodent models,
and the underlying estrogen paradox, re-
main incompletely understood. A per-
plexing question has remained: what are
the differences between a female mouse
(or female rat) and a female human?
M O L  M E D  2 0 : 6 2 5 - 6 3 8 ,  2 0 1 4  |  Y A N G  E T  A L .  |  6 2 5
Deletion of STAT5a/b in Vascular Smooth Muscle Abrogates
the Male Bias in Hypoxic Pulmonary Hypertension in Mice:
Implications in the Human Disease
Yang-Ming Yang,1 Huijuan Yuan,1 John G Edwards,2 Yester Skayian,2 Kanta Ochani,3 Edmund J Miller,3 and
Pravin B Sehgal1,4
Departments of 1Cell Biology & Anatomy, 2Physiology, and 4Medicine, New York Medical College, Valhalla, New York, United States
of America; and 3Center for Heart and Lung Research, The Feinstein Institute for Medical Research, Manhasset, New York, United
States of America
Chronic hypoxia typically elicits pulmonary hypertension (PH) in mice with a male-dominant phenotype. There is an opposite-sex
bias in human PH, with a higher prevalence in women, but greater survival (the “estrogen paradox”). We investigated the involve-
ment of the STAT5a/b species, previously established to mediate sexual dimorphism in other contexts, in the sex bias in PH. Mice
with heterozygous or homozygous deletions of the STAT5a/b locus in vascular smooth muscle cells (SMCs) were generated in
crosses between STAT5a/bfl/fl and transgelin (SM22α)-Cre+/+ parents. Wild-type (wt ) males subjected to chronic hypoxia showed sig-
nificant PH and pulmonary arterial remodeling, with wt females showing minimal changes (a male-dominant phenotype). How-
ever, in conditional STAT5+/– or STAT5–/– mice, hypoxic females showed the severest manifestations of PH (a female- dominant phe-
notype). Immunofluorescence studies on human lung sections showed that obliterative pulmonary arterial lesions in patients with
idiopathic pulmonary arterial hypertension (IPAH) or hereditary pulmonary arterial hypertension (HPAH), both male and female,
overall had reduced STAT5a/b, reduced PY-STAT5 and reduced endoplasmic reticulum (ER) GTPase atlastin-3 (ATL3). Studies of
SMCs and endothelial cell (EC) lines derived from vessels isolated from lungs of male and female IPAH patients and controls re-
vealed instances of coordinate reductions in STAT5a, STAT5b and ATL3 in IPAH-derived cells, including SMCs and ECs from the same
patient. Taken together, these data provide the first definitive evidence for a contribution of STAT5a/b to the sex bias in PH in the
hypoxic mouse and implicate reduced STAT5 in the pathogenesis of the human disease.
Online address: http://www.molmed.org
doi: 10.2119/molmed.2014.00180
Address correspondence to Pravin B Sehgal, Room 201, Basic Science Building, Depart-
ment of Cell Biology & Anatomy, New York Medical College, Valhalla, NY 10595. Phone:
914-594-4196; Fax: 914-594-4825; E-mail: pravin_sehgal@nymc.edu.
Submitted September 12, 2014; Accepted for publication November 20, 2014; Epub
(www.molmed.org) ahead of print November 21, 2014.
In addressing this question more
broadly, we realized the existence of sex-
bias mechanisms, in addition to E2 (and
steroid hormones), that drive male versus
female patterns of gene expression
(13–24). Specifically, that male versus fe-
male patterns of growth hormone (GH)
release (pulsatile versus continuous re-
spectively) by the pituitary under hypo-
thalamic control cause male versus fe-
male patterns of activation of signal
transducer and activator of transcription
(STAT)5a and STAT5b transcription fac-
tors has been well established in the last
15 years in other contexts (body growth,
breast, liver) (13–28). Thus, the major
transcription factors that mediate sex bias
resulting from dynamic-patterned fluctu-
ations of circulating GH are STAT5a and
STAT5b (19,23). Downstream of the
STAT5 transcription factors in sex-bias
determinism lie master transcription fac-
tors such as B-cell lymphoma 6 (Bcl6) and
cut-like homeobox 2 (CUX2), which, to-
gether with STAT5a/b, regulate the sex-
biased expression of >400–500 genes
(19,24,29–34). Indeed, it is already known
that a difference between humans and ro-
dents lies in circadian (diurnal versus
nocturnal) and quantitative differences in
the sex-biased patterns of circulating GH
(13,18,35,36). However, these GH-
STAT5–based mechanisms of sex bias
have never been evaluated in vascular bi-
ology or in the pathogenesis of PH.
STAT5a and STAT5b are ~90-kDa pro-
teins that are 96% related and have over-
lapping as well as distinct functions
(26–28). The two genes lie adjacent to each
other in the human and mouse genomes
at the STAT5a/b locus (25). There is an ex-
tensive literature establishing the cytokine,
GH and prolactin- and estradiol-17β (E2)
responsiveness of STAT5a/b transcription
factors through activation by Tyr-
 phosphorylation (PY) and/or Ser-
 phosphorylation (19,23,26,28). To investi-
gate the role of STAT5 species in
pulmonary vascular biology in vivo, espe-
cially in the sex bias observed in the hy-
poxic mouse model of PH, we developed
novel mouse lines that have heterozygous
or homozygous vascular smooth
muscle–specific deletion of the STAT5a/bfl/fl
locus using the SM22α-Cre+/+ approach
(25,37). For the present investigation, we
selected the male-dominant chronic hypo-
baric hypoxia model in the mouse
(C57BL/6 background) to study the influ-
ence of sex on development of hemody-
namic and histologic features of PH in
these tissue-specific conditional
STAT5a/b+/– and STAT5a/b–/– knockouts. We
also investigated STAT5 in cells in sections
of obliterative pulmonary arterial lesions
and in vascular cells isolated from lungs of
IPAH and HPAH patients of both sexes.
MATERIALS AND METHODS
Antibodies
Rabbit pAbs to STAT5a (sc-1081x, L-20),
STAT5a+b (sc-835x, C-17), Tyr-694-P-
STAT5 (PY-STAT5, sc-101806; reactive to
both a and b), murine monoclonal anti-
bodies (mAbs) to STAT5b (sc-1656, G-2),
and goat pAb to reticulon-4 (RTN4; also
called Nogo-B) (sc-11027, N-18) were from
Santa Cruz Biotechnology (Santa Cruz,
CA, USA), whereas rabbit pAb to atlastin-
3 (ATL3; ab104262) was from Abcam
(Cambridge, MA, USA). Mouse mAbs to
GM130 (#610823) and Vti1a (#611220)
were from BD Biosciences (San Jose, CA,
USA). The mAb to α-smooth muscle actin
(SMA) (A5228) and rabbit pAb to β-actin
(A2066) were from Sigma-Aldrich (St.
Louis, MO, USA). Alexa Fluor–tagged
donkey secondary antibodies were from
Life Technologies (Thermo Fisher Scien-
tific Inc., Waltham, MA, USA).
Generation of Mice with Smooth
Muscle–Specific Deletion of STAT5a/b
Protocols for mouse breeding, animal
care and experimental use of mice in the
present studies were approved by the In-
stitutional Animal Care and Use Commit-
tee of the New York Medical College. A
breeder pair of STAT5a/bfl/fl mice carrying
loxP inserts bracketing the entire STAT5
locus containing both a and b genes gen-
erated by Cui et al. (25) in C57BL/6 × 129J
background mice was provided by Lothar
Hennighausen (National Institutes of
Health, Bethesda, MD, USA). Hennig -
hausen and colleagues have previously
produced hematopoietic- and endothelial-
specific STAT5-null mice by mating these
STAT5-floxed mice with Tie-2-Cre+/+ mice;
however, such STAT5-null mice had
hypochromic anemia and reduced postna-
tal survival (38). For the present experi-
ments, STAT5a/bfl/fl mice were mated with
the SM22-Cre+/+ mice expressing Cre re-
combinase under the control of the mouse
transgelin smooth muscle protein 22α
promoter purchased from The Jackson
Laboratory (Bar Harbor, ME, USA) [stock
number 004746, Tg(Tagln-cre)1Her/J in
C57BL/6:129SJL background] (37). Poly-
merase chain reaction analysis of the tail
DNA using appropriate primers was used
to determine the genotype (wt and floxed
STAT5 alleles were from Cui et al. [25];
Cre alleles were from The Jackson Labora-
tory; primers are summarized in Supple-
mentary Table S1). Examples of STAT5a/b
wt or fl, and Cre-positive and -negative al-
leles are illustrated in Supplementary Fig-
ure S1. Cre-positive mice with the het-
erozygous STAT5a/bwt/fl or homozygous
STAT5a/bfl/fl genotypes were viable and
fertile and showed weight gain indistin-
guishable from the respective wt mice.
Control mice with Cre-positive
STAT5a/bwt/wt genotype used in the het-
erozygous deletion experiment were gen-
erated by crossing wt/wt C57BL/6 mice
with SM22-Cre+/+ mice. Control mice with
Cre-positive STAT5a/bwt/wt genotype used
in the homozygous deletion experiment
were littermates of the Cre-positive
STAT5a/bfl/fl mice; both wt and homozy-
gous knockout groups were offspring of
the crossbreeding between STAT5a/bfl/wt,
SM22-Cre+/– heterozygous mice; and thus,
background matched completely.
Assessment of PH and Lung Vascular
Remodeling in Mice after Chronic
Hypoxia
Groups of Cre-positive male and fe-
male mice (wt/wt compared with wt/fl in
the heterozygous deletion experiment
[STAT5+/–] and wt/wt compared with fl/fl
in the homozygous deletion experiment
[STAT5–/–]) were used at approximately
8 wks of age in the respective chronic hy-
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poxia experiments (n = 4–5 per group
per variable). Mice were exposed to hy-
pobaric hypoxia (0.5 atmospheres) for
7 wks; normoxia controls were left in
 ordinary room air (39,40).
The systemic blood pressure parame-
ters of the respective groups of normoxic
or hypoxic mice were measured during
the last week of each experiment by
using the tail-cuff method and a blood
pressure monitor (Non-Invasive BP Mon-
itor; Columbus Instruments, OH, USA).
The systolic and diastolic blood pres-
sures were determined using the Blood
Pressure Monitor Software (NIBPE, ver-
sion 1.23; Columbus Instruments).
Hemodynamic evaluation of the pul-
monary circulation was carried out by
using Millar catheterization beginning at
the end of 7 wks in mice that were anes-
thetized by using the ketamine/xylazine
cocktail (100 mg/kg ketamine, 10 mg/kg
xylazine i.p.); three to four mice derived
from different groups at random were
evaluated per day until all evaluations
were completed. A Millar catheter (SPR-
839 for the experiment in Figure 3 or
PVR-1030 for the experiment in Figure 4)
was used for the measurement of heart
rate and right ventricular systolic pressure
(RVSP) (Millar Instruments, Houston, TX,
USA). Numerical data for RVSP in hy-
poxic wt male mice were comparable to
those previously reported by right ven-
tricular (RV) catheterization (40). The ani-
mals were then euthanized, and the aorta
and left lung were removed and formalin
fixed (the right lung was snap frozen in
liquid N2). The heart was dissected to ob-
tain the ratio of right ventricle weight to
that of the left ventricle plus septum
(RV/LS+S) as a measurement of right
ventricular hypertrophy (RVH). The left
lung was formalin-fixed and paraffin-
 embedded for tissue sections (hema-
toxylin and eosin [H&E], van Giesson
elastin and Masson trichrome stains, and
quantitative immunofluorescence for
SMA, STAT5a+b [C-17 pAb] or PY-STAT5
[Tyr-694-STAT5a+b] or without primary
antibody). The extent of vascular remod-
eling in pulmonary arteries was quanti-
tated by (a) medial wall thickness (as 2×
wall thickness/outer vessel diameter in
elastin-stained sections measured along
two lines perpendicular to each other), (b)
number of SMA-positive vessels (diame-
ter <80 μm) per 10× field after immuno-
fluorescence staining, and (c) extent of
perivascular collagen deposition (blue
after Masson trichrome staining) (39,40).
Areal (two-dimensional) size of cells in the
tunica media was evaluated by z-stack im-
aging on H&E-stained sections of arterial
walls followed by three- dimensional re-
construction that then clearly displayed
the intercellular boundaries.
Immunofluorescence Analyses of
Lung Sections from IPAH and HPAH
Patients
Two separate sets of sections were used
in the present study. The first set con-
sisted of serial sections (5 μm) of forma-
lin-fixed, paraffin-embedded lung tissue
from patients with IPAH and from control
individuals without PAH (n = 6 each, in-
cluding males and females). These sec-
tions were provided by Rubin M Tuder
(then at the Johns Hopkins University
School of Medicine, Baltimore, MD, USA)
without any personal identifiers in com-
pliance with the guidelines of the Institu-
tional Review Board at the Johns Hopkins
University School of Medicine (the JHU
set); these sections, as used in the present
study, derive from our previous investiga-
tion of the Golgi tethers giantin and p115
in IPAH (42). Letter designations for indi-
vidual patients and controls correspond
to those in the article by Sehgal et al. (42).
In Figure 6, control (Ctrl)-A and Ctrl-F
were a 46-year-old female and a 25-year-
old female, respectively; whereas IPAH-A,
IPAH-B and IPAH-E were a 60-year-old
male, a 59-year-old female and a 53-year-
old female, respectively.
A second set of sections was provided
by the Tissue Processing Core at the Uni-
versity of Colorado, Aurora, and the Uni-
versity of Alabama, Birmingham, through
the auspices of the Pulmonary Hyperten-
sion Breakthrough Initiative (PHBI) and it
consisted of serial sections of lung samples
of male and female patients with IPAH
and HPAH (total n = 16) and male and fe-
male controls (total n = 12), as enumer-
ated in Supplementary Table S2 (the PHBI
set). These were provided without any
personal identifiers in compliance with
the guidelines of the Institutional Review
Board at the New York Medical College.
There was no explicit attempt to include
or exclude pediatric controls or patients.
These human lung sections were evalu-
ated by using H&E staining as well as in-
direct immunofluorescence for several
proteins. Data collection from lung sec-
tions was completed before obtaining in-
formation from the PHBI about age, pul-
monary artery (PA) pressures, pulmonary
vascular resistance, functional status and
treatment history of the respective pa-
tients. Thus, the conduct of this study was
blind with respect to these parameters.
Immunofluorescence studies using
these human lung sections were carried
out for STAT5a (using the L-20 pAb),
STAT5a+b (using the C-17 pAb), PY-
STAT5, ATL3 and RTN4/ Nogo-B, as de-
scribed earlier (42,43) by using respective
rabbit primary antibodies and donkey
anti-rabbit Alexa Fluor 594–tagged pAbs
(in red) as the secondary antibody. Con-
trols included slides exposed to irrele-
vant primary pAbs and also double-label
analysis by using anti-SMA in green
(using Alexa Fluor 488–tagged pAbs as
secondary). The STAT5b-specific mAb
(G2) was not reactive on archived human
lung sections.
Imaging was carried out by using a Zeiss
AxioImager M2 motorized microscopy
system equipped with a high-resolution
RGB HRc AxioCam camera and AxioVision
4.8.1 software in a 1,388 × 1,040 pixel high-
speed color capture mode (42–44). All data
within each experiment were collected at
identical imaging settings. Fluorescence
intensity was quantitated by using the
NIH ImageJ software (NIH, Bethesda, MD,
USA; http://rsb.info.nih.gov/ij/) with,
typically, six representative areas per ves-
sel wall or lesion image expressed as mean
pixel intensity. Background subtraction
within each image was derived from the
bronchial airspace. Fluorescence intensities
derived from individual images after back-
ground subtraction were normalized in
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terms of the strongest signal in each image
(typically from red blood cells or bronchial
epithelium), which was taken as 1.0.
Assessment of Proteins in Smooth
Muscle Cells and Endothelial Cells
Derived from Lungs of IPAH Patients
and Controls
Early passage (up to P4) smooth mus-
cle cell (SMC) and endothelial cell (EC)
cultures derived from vessels in periph-
eral lung areas of IPAH patients (total n =
12 SMC lines; n = 5 EC lines) and controls
(n = 9 SMC lines; n = 6 EC lines) of both
sexes, as enumerated in Supplementary
Table S2, were provided without any per-
sonal identifiers by the Cell Culture Core
of the PHBI at the University of Pennsyl-
vania School of Medicine. These cultures
were provided in compliance with the
guidelines of the Institutional Review
Board at the New York Medical College.
Number designations for individual pa-
tients correspond to those provided by
the Cell Core Facility of the PHBI (Sup-
plementary Table S2). As derived by
PHBI, the SMC lines were >95% SMA-
positive and the EC lines were >95% von
Willebrand factor (vWF)-positive. The
cells were grown for two passages at the
New York Medical College by using the
conditions recommended by the PHBI,
and suitable cultures (in T-25 flasks or
six-well plates) were used to prepare
whole cell extracts for Western blot analy-
ses or fixed (in cold 4% paraformalde-
hyde for 1 h), permeabilized (using digi-
tonin at 50 μg/mL for 5 min) and used
for immunofluorescence morphometry
(41,45,46). Western blot data were nor-
malized by using RTN4 as baseline and
are expressed in arbitrary units (AUs).
Statistical Evaluations
These evaluations were performed using
the two-tailed Student t test and single-
 factor analysis of variance (ANOVA) meth-
ods with (NCSS version 8, 2012; NCSS
LLC, Kaysville, UT, USA). Multiple group
comparisons were carried out by using
ANOVA (Tukey-Kramer, Newman-Keuls
and Tukey-Kramer tests). Cluster evalua-
tions in the cell-culture hypertrophy exper-
iments were carried out by using
Hotelling’s T2 Report and k-means cluster
analyses (NCSS version 8, 2012).
All supplementary materials are available
online at www.molmed.org.
RESULTS
Development of Mice with Deletion of
STAT5a/b in Vascular SMCs
Mouse lines with heterozygous and ho-
mozygous deletion of STAT5a/b in SMCs
were generated by crossbreeding
STAT5a/bfl/fl mice (13,15) with SM22α-Cre+/+
transgenic mice (see Materials and Meth-
ods, Supplementary Figure S1 and Sup-
plementary Table S1) (37). Such mice were
viable and fertile and showed weight gain
commensurate with that in the wt mice.
Verification of the deletion of STAT5a/b in
arterial SMCs in the knockout mice was
first carried out by characterizing
STAT5a/b expression in the tunica media
of the aorta. Both heterozygous (Supple-
mentary Figures S2A, S2B) and homozy-
gous (Supplementary Figures S3A, S3B)
knockouts showed reduced STAT5 im-
munofluorescence in the aortic tunica
media. Similarly, there was a marked re-
duction in transcripts for STAT5a and
STAT5b in RNA isolated from the aorta of
homozygous knockout mice (Supplemen-
tary Figure S3C and Table S3), and a
marked reduction in STAT5 species by
Western blotting in extracts of SMCs iso-
lated from the aorta of homozygous
knockout mice (Supplementary Figure
S3D) as well as in extracts of aortas of het-
erozygous knockout mice (not shown).
Despite this loss of STAT5 in the systemic
arterial tree, neither of the homozygous
nor heterozygous knockout mice of either
sex showed a significant change in resting
systolic, diastolic or mean blood pressure
using the tail-cuff assay (Supplementary
Figures S3E, S3F).
The consequences of the SM22α-Cre
driven heterozygous or homozygous
deletions of the STAT5a/b locus on STAT5
protein expression in the tunica media in
the pulmonary arterial tree were evalu-
ated using immunofluorescence methods
(Figure 1 and Supplementary Figure S2C).
A marked reduction in STAT5 immuno-
fluorescence was observed in the tunica
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Figure 1. Tissue-specific reduction in STAT5a/b expression in the tunica media of segments of
the main PA (A) as well as in a muscular (SMA-positive) PA segment within a lung section (B)
in STAT5–/– mice. Immunofluorescence studies were carried out using the C-17 rabbit pAb (for
STAT5a+b); black arrows point to the tunica media. Scale bars = 10 μm. The right side of each
panel shows quantitation of STAT5 immunofluorescence over the tunica media normalized with
respect to that over the tunica intima (A) or in terms of that observed in leukocytes in the
same slide (B) (n = 6 images valuated per group; mean ± standard error (SE); *P < 0.05 (t test).
media of PA segments after the heterozy-
gous (Supplementary Figure S2C) and ho-
mozygous deletions (Figures 1A, B).
As has been previously established in
other tissue and cell-type contexts (23,
47–49), there was little or no sex bias in the
baseline expression of STAT5a/b proteins
in aortic extracts derived from individual
male or female wt mice (Figure 2A) or in
extracts prepared from SMCs cultured
from pools of aorta (n = 5/ pool) derived
from wt male or female mice (Figure 2B).
However, SMC extracts derived from
STAT5–/– mice were confirmed to show di-
minished STAT5a/b (Figure 2B). Similarly,
there was little difference in STAT5 expres-
sion in the tunica media of PA segments in
lung sections between wt male versus fe-
male mice as judged using quantitative im-
munofluorescence analyses (Figures 2C–E).
Abrogation and Reversal of the 
Male-Dominant Sex Bias in PH
Development in Hypoxic
Heterozygous and Homozygous
STAT5a/b SMC-Specific Knockout Mice
Groups (n = 5) of male and female wt
or STAT5+/– mice were left in room air
(normoxia) or exposed to chronic hypoxia
for 7 wks and then evaluated for RVSP,
RVH and lung vascular remodeling (Fig-
ure 3 and Supplementary Figure S4).
There was little difference in baseline
RVSP in groups of male or female wt or
STAT5+/– mice kept under normoxia (Fig-
ure 3A). However, after exposure to hy-
poxia, male wt mice developed increased
RVSP and RVH as well as pulmonary ar-
terial remodeling with increased wall
thickness. As expected, female wt hypoxic
mice showed less hemodynamic and his-
tologic changes of PH. Strikingly, female
STAT5+/– mice developed PH and pul-
monary arterial remodeling dramatically
more severe than that in hypoxic wt fe-
males (Figures 3A–D and Supplementary
Figure S4). Even among STAT5+/– mice,
females showed more severe changes
than males. Histologically, increased pul-
monary arterial wall thickness in female
hypoxic STAT5+/– mice included increased
collagen deposition in the tunica adventi-
tia/perivascular region (Figure 3E and
Supplementary Figure S4B).
The abrogation of the male dominance
in the development of hypoxic PH was
observed to an even greater extent in ho-
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Figure 2. Expression of STAT5 species in differ-
ent vascular tissues of male and female wt
and STAT5–/– mice. (A) Aortic extracts from in-
dividual duplicate male and female wt mice
were Western blotted for STAT5a (using L-20
pAb), STAT5a+b (using C-17 pAb) or β-actin.
B: SMCs were cultured from aortic segments
of pools of mice (n = 5 each) of the indi-
cated genotype and sex. The cell extracts
were then evaluated by Western blotting for
STAT5 species as in A. (C–E) Quantitative
evaluation of anti-STAT5a/b immunofluores-
cence (C-17 pAb) in PA segments in lung
sections from male and female wt mice (n =
2 mice per group with a total of 18 arterial
segments quantitated) in two different ways:
average pixel intensity over arterial walls
after subtracting background in each indi-
vidual slide over the bronchial air space (D)
and normalized fluorescence intensity over
arterial walls expressed as a ratio to that
over the bronchial epithelium within the
same individual slide (E). n = arterial seg-
ments in 2 different mice quantitated per
group; mean ± SE; NS, not significant (t test).
Figure 3. Conversion of the male-dominant PH response to chronic hypoxia in wt mice to
a female-dominant response in heterozygous STAT5+/– mice. Respective groups (n = 5) of
approximately 8-wk-old mice of either gender and indicated genotype were exposed to
hypobaric hypoxia for 7 wks or kept in room air. At the conclusion of the experiment, vari-
ous parameters of PH were assessed (RVSP in A, RV/LV+S weight in B, medial wall thickness
[as % outer diameter] in C, number of SMA-positive vessels per 10× field in D, and extent
of tunica adventitia/perivascular collagen deposition as evaluated by Trichrome staining
[blue] expressed in AUs in E). Data in each chart summarize mean ± SE; *P < 0.05 using
multiple-group ANOVA and pair-wise t test.
mozygous STAT5–/– knockout mice (Fig-
ure 4 and Supplementary Figure S5). The
data from this experiment again verified
that development of hypoxic PH in wt
mice displayed a male-dominant pheno-
type with respect to every parameter in-
vestigated (Figure 4 and Supplementary
Figure S5). However, after STAT5–/– knock-
out, female mice developed the severest
increases in RVSP and RVH, and arterial
remodeling—even more than that ob-
served in the male knockouts. Moreover,
even among the male mice, the STAT5–/–
males showed more severe disease than
wt males (Figures 4A, C, D). Thus, both
male and female STAT5–/– homozygous
knockout mice had more severe disease
than their wt counterparts, with female
knockouts showing the severest disease of
all. Histologically, the increased pul-
monary arterial wall thickness in hypoxic
female STAT5–/– mice was accompanied by
increased collagen deposition in the tunica
adventitia/ perivascular region (Figure 4E
and Supplementary Figure S5B).
At the cellular level, STAT5–/– knockout
by itself did not lead to cell hypertrophy
in the tunica media either in the male or
female mouse (Figures 5A–C). After hy-
poxia, SMC hypertrophy was evident 
in male wt mice but not in the female
(Figures 5A, C). In contrast, marked 
SMC hypertrophy was evident in the tu-
nica media of both male and female
STAT5–/– knockout mice after hypoxia
(Figures 5A–C). The z-stack imaging and
three-dimensional  reconstruction helped
in defining the  intercellular boundaries
between SMCs in the tunica media (two
examples are shown in Figure 5B). Quan-
titation of the cellular hypertrophy in the
tunica media of arterial segments in
lungs of mice in the respective control
and experimental groups is summarized
in Figure 5C. Overall, SMC hypertrophy
was a key cellular event in the pathogen-
esis of PH in this mouse model.
Implications in Human PAH
The relevance of the preceding data
showing development of marked PH in
hypoxic mice with SMC-specific condi-
tional deletion of STAT5a/b to the patho-
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Figure 4. Conversion of the male-dominant PH response to chronic hypoxia in wt mice to
a female-dominant response in homozygous STAT5–/– mice. Respective groups (n = 4–5) of
approximately 8-wk-old mice of either gender and indicated genotype were exposed to
hypobaric hypoxia for 7 wks or kept in room air. At the conclusion of the experiment, vari-
ous parameters of PH were assessed (RVSP in A, RV/LV+S weight in B, medial wall thickness
[as % outer diameter] in C, number of SMA-positive vessels per 10× field in D, and extent
of tunica adventitia/perivascular collagen deposition as evaluated by Trichrome staining
[blue] expressed in AUs in E). Data in each chart summarize mean ± SE. *P < 0.05 using
multiple-group ANOVA and pair-wise t test.
Figure 5. SMC hypertrophy in the tunica media of pulmonary arterial segments of hypoxic
STAT5–/– knockout mice. (A) H&E staining of lung sections of male and female wt normoxic
and hypoxic mice and in male and female STAT5–/– normoxic and hypoxic mice from the
experiment in Figure 4. Scale bars = 10 μm. (B) Three-dimensional representation of z-stack
images of two illustrative examples of pulmonary arterial walls in the experiment summa-
rized in A. (C) Quantitation of the areal size of cells (mean ± SE) in the tunica media of ar-
terial walls (this is an SMA-positive cell type; data not shown) in the respective groups in A
using the method in B; n > 200 cells derived from three mice from each group were enu-
merated; *P < 0.05 using multiple-group ANOVA and pair-wise t test.
genesis of PAH in humans was then in-
vestigated. It was already striking that
vascular cell hypertrophy was a key ob-
servation in the arterial walls of hypoxic
STAT5–/– knockout mice of both sexes
(Figures 5A–C) as well as in the oblitera-
tive onion-skin lesions in IPAH (Figure 1
in Sehgal et al. [42]; Figure 15 in Lee et al.
[45]). We have previously shown that
acute siRNA-mediated knockdown of
STAT5a/b in pulmonary vascular cells
led to the development of a unique cystic
endoplasmic reticulum (ER) and dilated
and fragmented Golgi apparatus pheno-
type with deposition of RTN4 (an ER
structural protein) and ATL3 (an
ER/Golgi resident GTPase) at the cyst-
zone boundaries, with one to three large
juxta-nuclear cysts comprising dilation of
the ER space between the inner and
outer nuclear membranes resulting in a
lunate distortion of the nuclei (45,46).
Functionally, there was reduction of an-
terograde of member proteins including
BMPR2 trafficking) (41). Thus, we inves-
tigated the expression of STAT5a/b,
ATL3 and RTN4 in obliterative arterial
lesions in human IPAH and HPAH by
immunofluorescence analyses (42,43), 
as well as the presence of hypertrophic
cells with enlarged ER and lunate distor-
tion of nuclei (45,46) in such lesions (Fig-
ures 6, 7).
Figures 6A and B illustrate a loss of
STAT5a in the obliterative lesions in male
and female IPAH patients (JHU set). 
Figure 6C shows an irrelevant antibody
control, and Figure 6D shows a double-
label analysis verifying that the oblitera-
tive lesions shown in Figure 6A con-
tained SMA-positive cells. Figures 6E
and F show a dramatic loss of ATL3 in 
illustrative obliterative lesions in an
IPAH patient and the quantitation of this
reduction.
These studies were extended to lung
sections of sex-segregated patients with
HPAH, IPAH and controls in the PHBI set
(Supplementary Table S2) by using two
different anti-STAT5 pAbs (STAT5a-spe-
cific L-20 and STAT5a+b-reactive C-17) as
well as for PY-STAT5, ATL3 and RTN4. To
begin with, evaluation of these sections
using H&E staining readily showed the
presence of hypertrophic cells with juxta-
nuclear cysts and lunate distortion of the
nucleus, reminiscent of the cell phenotype
produced by acute siRNA-mediated
knockdown of STAT5a/b. Figure 15 in
Lee et al. (45) had shown an example of
such cells in obliterative lesions of a fe-
male patient with IPAH; the present Fig-
ure 7A illustrates an example of cells with
this phenotype in lesions in a male patient
with HPAH. Serial sections from the set
corresponding to the control and HPAH
patient shown in Figure 7A, as well as
from additional male and female IPAH
and HPAH patients and controls, were
then probed for STAT5a, STAT5a+b, PY-
STAT5, ATL3 and RTN4 (Figures 7B–E). In
the immunofluorescence data shown in
Figure 7B, there was reduced STAT5, PY-
STAT5 and ATL3 but increased RTN4 ex-
pression. Quantitative analyses for STAT5
expression in arterial tunica media of
male and female controls, as well as in
obliterative vascular lesions in male and
female PAH patients in the PHBI set,
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Figure 6. Reduced STAT5 and ATL3 in obliterative lesions of human IPAH (JHU set). Represen-
tative formalin-fixed paraffin-embedded sections of lungs from human IPAH patients and
controls (female: f; male: m) as previously reported in Sehgal et al. (42) (JHU set designa-
tions Ctrl-A, Ctrl-F, IPAH-A, IPAH-B and IPAH-E as in Sehgal et al. [42]) were immunostained for
STAT5a (L-20 pAb) and for ATL3 (Abcam pAb). (A) STAT5a immunofluorescence; thick arrows
point to normal pulmonary arteries in Ctrl-F; thin arrows point to obliterative lesions in IPAH
patients. Scale bar = 45 μm. (B) Quantitation of average fluorescence pixel intensities for
STAT5a in Ctrl vessels and IPAH lesions (n); mean ± SE. *P < 0.05 (t test). (C) Negative control
using irrelevant primary pAb. (D) Double-label imaging validating that the obliterative le-
sions with reduced STAT5a represent cells that are SMA-positive. Scale bar = 40 μm. (E) ATL3
immunofluorescence; thick arrows point to normal pulmonary arteries in Ctrl-A with greatest
fluorescence in the endothelium; thin arrows point to different obliterative lesions in an IPAH
patient. Internal and external elastic laminas in this analysis were visualized by autofluores-
cence in green. Scale bar = 45 μm. (F) Quantitation of average fluorescence pixel intensi-
ties for ATL3 in Ctrl vessels and IPAH lesions (n); mean ± SE. *P < 0.05 (t test). 
showed a marked reduction of STAT5 in
PAH patients of both sexes (Figure 7C
and Supplementary Table S2). Whereas
reduction, overall, groups of male and fe-
male PAH patients both showed reduced
STAT5 in the pulmonary vascular obliter-
ative lesions. Tissue sections from a subset
of the PAH patients were evaluated for
PY-STAT5 and ATL3 (Figures 7D, E). The
data obtained showed the reduction of
PY-STAT5 and ATL3 in cells in obliterative
vascular lesions in both male and female
PAH patients.
Reduced STAT5 Correlates with Cell
Hypertrophy in IPAH-Derived SMC
Lines
The above immunofluorescence data
derived from lung sections of PAH pa-
tients showing reductions in STAT5a,
STAT5a+b and ATL3 in the same oblitera-
tive lesion raised the question whether
cells derived from lung vessels of IPAH
patients might also show coordinate re-
ductions in these molecules. A related
question derived from the H&E imaging
data shown in Figure 7A was whether
vascular cells derived from PAH patients
were hypertrophic and to what extent.
Thus, cell imaging studies and Western
blot analyses of the primary cell lines pro-
vided by the PHBI (Supplementary Table
S2) were carried out. For these studies
each cell line was grown in triplicate wells
of a six-well plate for imaging and simul-
taneously in a T-25 flask for preparing cell
extracts. Eventually, 9 control SMC and 10
IPAH SMC lines were evaluable by phase
contrast microscopy. By this inspection, all
9 control SMC lines consisted of small
cells, whereas 4 of 11 IPAH SMC lines
consisted of similar small cells. The re-
maining 7 of 11 IPAH SMC lines consisted
of enlarged hypertrophic cells (see below).
The EC lines did not show such overt size
differences. In contrast to evidence of
SMC hypertrophy in IPAH-derived pri-
mary cell lines, little size difference was
evident among the control and IPAH-de-
rived EC lines (data not shown).
Figure 8A is a compilation of one set of
three controls and three IPAH-derived
female SMC lines corresponding to the
Western blot analysis of these cell ex-
tracts in Figure 8B. Morphometry data
pertaining to cell size and Golgi appara-
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the individual STAT5 expression levels
summarized in Figure 7C reveal a patient-
specific heterogeneity in the extent of this
Figure 7. Summary of data showing reduced STAT5 and ATL3 in obliterative vascular lesions
in male and female IPAH and HPAH patients (PHBI set). (A) H&E staining of a PA segment in
a male control (#6) and an obliterative lesion in a male patient with HPAH (#10) provided
by PHBI (Supplementary Table S2). Scale bar = 30 μm. Insets show boxed areas at higher
magnification. (B) Illustrative immunofluorescence analyses for STAT5a (L-20 pAb), STAT5a+b
(C-17 pAb), PY-STAT5, ATL3 and RTN4/Nogo-B in PA segments from the same control male
patient (top row; white arrows) and obliterative vascular lesion from the same HPAH pa-
tient (bottom row; white arrows) in A. Scale bar = 50 μm. (C) Quantitation of STAT5 immuno-
fluorescence in tunica media of multiple arterial segments or obliterative vascular lesions in
lung sections from control or PAH patients expressed in normalized arbitrary units (mean ±
SE). Imaging data were collected from an average of five vessels/lesions per patient, and
fluorescence intensities over vessels/lesions were expressed as a fraction of the highest in-
tensity observed within each image (in epithelial cells or red blood cells). Patient number
corresponds to the lab ID number listed in Supplementary Table S2; dashed line = overall
group average; *P < 0.001 (t test). (D, E) Quantitation of PY-STAT5 and ATL3 immunofluores-
cence in normalized arbitrary fluorescence units in tunica media of multiple arterial seg-
ments or obliterative vascular lesions in lung sections from a subset of patients in B (n = av-
erage of 5 vessels/lesions per patient; mean ± SE); *P < 0.001 (t test).
tus size (and STAT5a levels by Western
blots) for 10 such SMC cell lines (5 con-
trol and 5 IPAH-derived) are enumerated
in Table 1. Overall, SMCs from the IPAH-
derived group included lines that were
hypertrophic when compared with those
derived from controls. It is striking that
these hypertrophic IPAH-derived SMCs
also showed enlargement of the Golgi
apparatus (Figure 8A), confirming our
previous data derived from analyses of
the Golgi size in cells in lung sections of
control and IPAH patients (42).
An inspection of the Western blot
shown in Figure 8B illustrates that as
with the immunofluorescence data de-
rived from IPAH lung sections (Figure 6),
there were IPAH-derived SMC lines that
showed reduced expression of STAT5a,
STAT5b and ATL3. Moreover, reduced
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Figure 8. Relationship between cellular hypertrophy of IPAH-derived SMCs and STAT5 expression. (A) Representative SMC cell lines derived
from three control and three IPAH patients were probed by triple-label immunofluorescence imaging for STAT5a, a Golgi marker (GM130
or Vti1a) and DAPI. The present study was blinded with respect to the age of the patients (indicated in parentheses). Scale bar = 20 μm;
the same scale bar applies to control and IPAH images. The paraformaldehyde-fixed cells were permeabilized using digitonin; thus, the
anti-STAT5a pAb does not penetrate into the nucleus (24). (B) Composites showing Western blot analyses of equal protein aliquots de-
rived from extracts of cultures of the same SMC lines as in A and additional EC lines (Supplementary Table S2). Blots were probed for
STAT5a (L-20 pAb), STAT5b (G-2 mAb), the ER-resident GTPase ATL3, the Golgi SNARE Vti1a, the ER structural protein RTN4 (Nogo-B) and β-
actin. Boxed areas in B highlight individual examples with the triple loss of STAT5a, STAT5b and ATL3 (all of which were derived from IPAH
patients). (C, D) Investigator-independent morphometric cluster analyses of cells in 10 SMC cell lines derived from control (n = 5; closed
diamonds) and IPAH lungs (n = 5; open squares) for cell size (mean ± SE), for Golgi apparatus size (mean ± SE) and for STAT5a expression
enumerated in Table 1; error bars not visible correspond to small numerical values, which are all tabulated in Table 1. The k-means cluster
analysis optimized two clusters (the open squares cluster, which contained all the IPAH lines, and the closed diamonds cluster, which con-
tained all the control lines). Statistical evaluation of distributions of IPAH (open squares) and Ctrl (closed diamonds) clusters in two-way
and three-way comparisons using k-means cluster analyses gave P < 0.001 in all intercluster comparisons.
Table 1. Morphometry of cells in control- and IPAH-derived SMC cell lines.
Patient SMC number Cell size (μm2)a Golgi size (μm2)a STAT5a AUsb
Control 54 423 ± 16 (84) 32 ± 8 (47) 0.95
Control 98 741 ± 42 (55) 52 ± 4 (60) 0.41
Control 102 648 ± 72 (24) 107 ± 40 (72) 0.90
Control 103 870 ± 71 (24) 173 ± 42 (72) 0.55
Control 104 629 ± 72 (22) 55 ± 3 (121) 0.46
IPAH 25 4,424 ± 360 (73) 406 ± 94 (23) 0.06
IPAH 36 13,040 ± 1,808 (18) 1,150 ± 123 (16) 0.17
IPAH 66 4,889 ± 773 (27) 553 ± 75 (28) 0.21
IPAH 74 8,860 ± 1,326 (11) 566 ± 147 (16) 0.17
IPAH 105 6,360 ± 1,327 (18) 361 ± 89 (25) 0.28
All combined
Control, mean ± SE 662 ± 82 84 ± 29 0.65 ± 0.13
IPAH, mean ± SE 7,515 ± 1,770 607 ± 158 0.18 ± 0.04
P 0.0025 0.0066 0.0036
aData are mean ± SE (number of cells enumerated). 
bIn normalized arbitrary units by Western blotting of cell extracts. Statistical testing used 
k-means cluster analysis.
STAT5a/b and reduced ATL3 were also
observed in both SMC and EC lines de-
rived from the same IPAH patients (pa-
tients 36 and 105). Thus, there is a simi-
larity (Figures 6, 7) in data derived from
lung sections and from evaluation of cell
lines (Figure 8).
The relationships between STAT5a con-
tent (by Westerns), cell hypertrophy and
Golgi apparatus enlargement were tested
in a subset of 10 SMC cell lines for which
data regarding STAT5 protein levels as
well as cell and organellar morphometry
were evaluated (n = 5 controls and n = 5
IPAH-derived; Table 1). Investigator-in-
dependent cluster analyses were carried
out by using all of the Western blot quan-
titation, cell size and Golgi apparatus size
measurements for the 10 cell lines by
using Hotelling’s T2 Report procedure in-
corporating two parameters at a time
(NCSS version 8, 2012). With each pair of
parameters, this process optimized two
clusters: one cluster (open squares) that
contained all the IPAH lines and another
(solid diamonds) that contained all the
control lines (Figures 8C, D). Statistical
evaluation of distributions of IPAH and
Ctrl clusters in two- and three-way com-
parisons using k-means cluster analyses
gave P < 0.001 in all intercluster compar-
isons. Thus, low STAT5 expression clus-
tered with cell hypertrophy and enlarged
the Golgi apparatus in IPAH-derived
SMC lines in a multiparameter pattern.
DISCUSSION
To focus first on the mouse data, the
hypothesis that STAT5a/b may play a
causal role in the pathogenesis of PH
was tested in the hypoxic mouse model.
The observations that heterozygous or
homozygous deletions of the STAT5a/b
locus in SMCs resulted in female mice
that developed the severest PAH in re-
sponse to chronic hypoxia abrogating the
otherwise male-dominant phenotype in
this model confirm a role for STAT5 in
the pathogenesis of PH. This is the first
time that STAT5 species have been defin-
itively implicated in sex-dependent ef-
fects in any aspect of vascular biology. A
role of STAT5 in sex- dependent and sex-
independent mechanisms in the patho-
genesis of hypoxic-PH was suggested by
the observation that although the female
STAT5–/– knockout mice developed the
severest disease in response to chronic
hypoxia, even the male knockout mice
had more severe disease than the wt
males (Figure 4) and displayed markedly
increased SMC hypertrophy, but only in
combination with hypoxia (Figure 5).
STAT5–/– knockout by itself did not lead
to SMC hypertrophy in the mouse pul-
monary arterial wall (Figure 5).
To focus next on studies characterizing
STAT5 expression in human disease–
 derived lung sections, there was reduced
STAT5a/b, reduced PY-STAT5 and re-
duced ATL3 in cells in obliterative lesions
in the majority of the human IPAH and
HPAH patients evaluated, both male and
female. While there were clear variations
between individual patients (Figure 7),
and even in lesions in the same patient
(not shown), the overall trend was a re-
duction of STAT5a/b, PY-STAT5 and
ATL3 in PAH in both sexes. A limitation
in interpreting these data is that these
lung tissue sections represent late-stage
disease. The same limitation applies to
the SMC and EC lines derived from pa-
tient lungs, with the additional limitation
that cells in a derived line may not repre-
sent solely those that originate within the
vascular lesion but also include nearby
normal cells. Nevertheless, the discovery
of a pattern of reduced STAT5a, STAT5b
and ATL3 in IPAH- derived SMC and EC
lines (in two instances the two cell types
isolated from the same patient), as well
as in lesions in lung sections, suggests an
underlying biological significance. The
clustering of low STAT5 expressing
IPAH-derived lines into a hypertrophic
cluster, in comparison to SMC lines de-
rived from controls, is reminiscent of the
marked SMC hypertrophy in PA ob-
served in male and female hypoxic
STAT5–/– mice. The biological significance
of this clustering is further enhanced by
our previous observation that mouse em-
bryo fibroblasts derived global
STAT5a/b–/– mice displayed transient cell
hypertrophy, marked Golgi enlargement
and fragmentation as well as a cystic ER
change for 1–2 d after plating in cell cul-
ture (see Figures 11 and 12 in Lee et al.
[45]). The mechanisms that lead to this
cellular hypertrophy and accompanying
altered organellar and growth properties
remain to be elucidated.
Our focus on STAT5 in the pathogene-
sis of PAH (a schematic is shown in Fig-
ure 9) arose from the recognition in the
last 3–4 years (41,43–46) that the subcellu-
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Figure 9. The STAT5a/b transcription factor hub in pulmonary hypertension.
lar phenotype produced by siRNA-
 mediated knockdown of STAT5a/b in
human pulmonary ECs and SMCs (cystic
ER/fragmented Golgi apparatus/lunate
distortion of the nucleus) was similar to
that reported in 1977 and 1979 by Smith
and Heath in endothelial cells in the
rat/hypoxia model and in cells in plexi-
form lesions in IPAH based on their elec-
tron micrographic studies (50,51). In a
pilot study (45), we observed that cells in
obliterative lesions in IPAH showed a loss
of STAT5a accompanied by the cystic
ER/Golgi enlargement/lunate nucleus
and ER stress phenotype. These data led
us to suggest that loss of STAT5a/b might
contribute causally to the pathogenesis of
PAH, through genomic and novel nonge-
nomic mechanisms (for example, inhibi-
tion of BMPR2 trafficking to the plasma
membrane and its signaling) discovered
by us (41,43–46) (Figure 9). The present
study represents a direct test of this hy-
pothesis by using conditional STAT5a/b+/–
and STAT5a/b–/– knockout mice.
Of the seven STAT transcription fac-
tors (STAT1, 2, 3, 4, 5a, 5b and 6), only
STAT5a and STAT5b mediate sexual di-
morphism (23,24,26,28). STAT5a/b are
activated through Tyr- and/or Ser-phos-
phorylation by cytokines, growth factors,
GH and prolactin and modulated by E2
(Figure 9). The work of Waxman and col-
leagues over the last decade has shown
that mechanisms of sexual dimorphism
converging on STAT5a and STAT5b (in
mice) originate mainly from the sex-de-
pendent dynamic patterns of release of
GH from the pituitary, either in a pul-
satile (male) or continuous (female) man-
ner leading to pulsatile or continuous
patterns of activation of STAT5 species
(by Tyr-phosphorylation) (13–28,36) 
(Figure 9). This patterned low-level 
activation of PY-STAT5 species by GH 
in different tissues leads to the differen-
tial expression of 400–500 distinct genes
in a male- or female-specific phenotype
(Figure 9). As a baseline issue in our
studies, vascular cells and tissues from
male and female mice expressed similar
levels of unphosphorylated STAT5a/b
(U-STAT5a/b; Figure 2). Waxman and
colleagues have emphasized that it is the
quantitative differences in the dynamic
GH-driven patterns of PY-STAT5 activa-
tion that determine the sex bias in down-
stream gene expression in their mouse
studies (23,24). That both STAT5a/b+/– and
STAT5a/b–/– knockout mice showed rever-
sal of the sex bias in hypoxia-induced PH
and its increased severity is consistent
with the concept that small quantitative
changes in the extent and pattern of
STAT5a/b activation suffice to determine
the underlying sex bias. The relationship
between the extent of STAT5 reduction
and disease severity remains an impor-
tant open question.
In the context of PH in mouse and hu-
mans, STAT5a/b are affected by multiple
signaling and miRNA pathways and, in
turn, regulate other transcription factors,
cell-cycle regulators and miRNAs already
known to be important in the pathogene-
sis of this disease (Figure 9). The new ob-
servations from the present studies reflect
an overlay of sex bias over these mecha-
nisms driven, we suggest, by dynamic
GH patterns in the male and female,
quantitatively different between mouse
and humans (Figure 9). Irrespective of
the upstream mechanisms that regulate
levels of STAT5a/b expression in cells
(such as by regulating its transcriptional
expression, mRNA degradation through
miR-222 or proteasomal degradation; Fig-
ure 9), the downstream sex-bias mecha-
nisms already identified by Waxman and
colleagues include transcription factor
hubs such as CUX2 and Bcl6 regulated by
dynamic (pulsatile or continuous) activa-
tion of PY-STAT5a/b by GH in a sex-
 specific manner (17,19,37). In turn, these
transcription factor hubs affect hundreds
of target genes (including cytokines,
BMPR2 and STAT5a expression and
Smad signaling) and cell-cycle checkpoint
genes and affect or are themselves af-
fected by micro-RNAs already implicated
in PAH (for example, miR-155 and
miR-21) (29,33,34,52–56) (Figure 9). The
new mouse model developed by us pro-
vides a novel technology platform for
elucidating the molecular basis for how
loss of STAT5 promotes pulmonary arte-
rial SMC hypertrophy and increased PH.
Sex-specific modulation of Bcl6/cytokines
secondary to STAT5a/b loss represent at-
tractive downstream candidate molecular
mechanisms (17,19,32,52–56).
Most investigators thus far have con-
sidered mechanisms of sex bias in PH in
rodent models (male predominant) and
humans (female predominant) mainly in
terms of differences due to sex hormones
(1–8). The present study highlights a
complementary mechanism, largely in-
dependent of steroid hormones, con-
tributing to this sex bias in terms of male
or female patterns of activation of PY-
STAT5 by circulating GH. Whether ex-
ogenous estrogens might be protective in
the hypoxic STAT5–/– male or female
knockout mouse model of PH remains
an open question.
In cystic fibrosis, there is a well-
 established “gender gap” such that
women get the disease earlier and in
more severe form (57,58). However, un-
like the protective effect of E2 in rodent
models of PH (22), exogenously adminis-
tered E2 exacerbated the disease in the
male cystic fibrosis knockout mouse ac-
companied by elevated Th17-associated
proinflammatory mediators (59).
The combination of hypoxia with the
inhibitor SU5416 has been used to derive
a rodent model of PH that develops ex-
tensive pulmonary arterial remodeling
(60,61). The inclusion of SU5416 in this
model has customarily been presented as
the addition of a “VEGF receptor 2 an-
tagonist” (4,60,61). Intriguingly, in a re-
cent review, Lahm et al. (4) point to their
data in this model, suggesting little or no
sex bias. We note that it is known that
hypoxia activates PY-STAT5 (62,63) and
that SU5416 also inhibits activation of
PY-STAT5 (64,65). This result raises the
possibility that an absence of sex bias in
the hypoxia + SU5416 model may derive
from the already known ability of
SU5416 to inhibit PY-STAT5 activation
(64,65). Thus, the SU5416-treated hypoxic
rodent would be analogous to the
STAT5–/– knockout hypoxic mouse. Addi-
tionally, polycythemia has been observed
in hypoxic mice, and erythropoietin
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(Epo) and HIF-2 isoforms have been
shown to participate in this process
(66,67). Because it is also known that Epo
signals through STAT5 in erythroid line-
age cells (28) and that polycythemia can
affect SMC reactivity by affecting NO
bioavailability (68), future studies of hy-
poxia-induced polycythemia in our con-
ditional STAT5a/b–/– mice might prove 
insightful.
In studies of human IPAH- and
HPAH-derived lung sections, while there
was patient-specific variation, these tis-
sue materials showed reduced nonphos-
phorylated STAT5a/b and reduced PY-
STAT5 in obliterative lesions in both
male and female patients, together with
reduced ATL3. Overall, this triple-loss
phenotype was present in human vascu-
lar lesions equivalently in both groups of
male and female patients. The absence of
an evident sex bias in the loss of
STAT5a/b may reflect a limitation of
studies by using tissue sections from pa-
tients with late-stage disease (as avail-
able from PHBI) or may represent the in-
trinsic complexity and heterogeneity of
this disease. A reduction in PY-STAT5 in
both males and females would suggest
similar downstream changes (Figure 9)
in both sexes, at least in late-stage dis-
ease. Intriguingly, it has been estimated
that dasatanib, a tyrosine kinase inhibitor
also known to inhibit STAT5 signaling
and downregulate STAT5 target gene ex-
pression (69), led to development of PH
in approximately 0.45% of leukemia pa-
tients receiving this medication, with the
identified cases occurring primarily in
women (70).
CONCLUSION
To summarize, we developed a novel
female-dominant mouse model of PH that
can be used to understand the molecular
pathogenesis of this disease. The mice
with a smooth muscle–specific deletion of
STAT5a/b converted the male-dominant
hypoxia-induced PAH to a  female-
dominant phenotype. Although the
knockout females developed the severest
disease, disease severity was also higher
in the knockout males compared with wt
males. These data provide the first defini-
tive evidence for the causal involvement
of STAT5 in the pathogenesis of PAH. The
data also draw attention to an alternative
novel mechanism to understand the sex
bias seen in human and rodent PH based
on the GH-STAT5 sex-bias axis, with dif-
ferences between humans and rodents
suggested to arise from quantitative and
circadian differences in circulating GH
patterns in males and females in the re-
spective species. We also provide evi-
dence for a loss of STAT5 in cells in oblit-
erative pulmonary vascular lesions in
human IPAH and HPAH, in both men
and women in late-stage disease. Candi-
date downstream molecular mechanisms
leading to PAH pathogenesis may include
disruption of transcription factor hubs
regulated by STAT5/Bcl6 that affect cy-
tokine biology, cell cycle progression and
transition into mitosis. Thus, the data sug-
gest new molecular targets that could be
manipulated to modify the pathogenic
cause of this devastating condition.
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